Medicare Enrolled

Dr. Priyank Chaudhary, M.D., MBS

Rheumatology · Raleigh, NC
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
11009 INGLESIDE PL STE 303, Raleigh, NC 27614
9193413603
In practice since 2011 (14 years)
NPI: 1437447844 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chaudhary from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chaudhary? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Chaudhary

Dr. Priyank Chaudhary is a rheumatology specialist in Raleigh, NC, with 14 years of NPI registration. Based on federal Medicare data, Dr. Chaudhary performed 4,420 Medicare services across 462 unique beneficiaries.

Between the years covered by Open Payments, Dr. Chaudhary received a total of $16,921 from 46 pharmaceutical and/or device companies across 251 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Chaudhary is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 14 years in practice ▲ 4,420 Medicare services $16,921 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,420
Medicare services
Bottom 45% in NC for rheumatology
462
Unique beneficiaries
$37
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~316 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
3,770 $26 $200
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
236 $85 $213
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
160 $88 $355
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
95 $123 $286
New patient office visit, complex (60-74 min) 61 $164 $409
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
46 $111 $328
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
28 $1 $32
Ultrasound-guided large joint aspiration or injection
This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint.
12 $75 $179
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
12 $39 $160
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
89.2% high complexity
0.9% medium
9.9% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$16,921
Total received (2018-2024)
Avg $2,417/year across 7 years
Top 17% in NC for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
251
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$8,361 (49.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,033 (29.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,527 (20.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,852
2023
$4,925
2022
$878
2021
$540
2020
$1,635
2019
$6,944
2018
$148

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$231
Amgen Inc.
$189
Abbott Laboratories
$174
Boehringer Ingelheim Pharmaceuticals, Inc.
$143
PFIZER INC.
$140
GlaxoSmithKline, LLC.
$123
Novartis Pharmaceuticals Corporation
$95
SOBI, INC
$75
AstraZeneca Pharmaceuticals LP
$71
Alexion Pharmaceuticals, Inc.
$71
Organon Llc
$66
GENZYME CORPORATION
$62
UCB, Inc.
$60
Aurinia Pharma U.S., Inc.
$54
ANI Pharmaceuticals, Inc.
$51
Lilly USA, LLC
$50
ABBVIE INC.
$46
Fresenius Kabi USA, LLC
$34
Phathom Pharmaceuticals, Inc.
$19
Genentech USA, Inc.
$19
Medtronic, Inc.
$18
Actelion Pharmaceuticals US, Inc.
$17
Takeda Pharmaceuticals U.S.A., Inc.
$17
E.R. Squibb & Sons, L.L.C.
$15
Merck Sharp & Dohme LLC
$14
Top 3 companies account for 32.1% of 2024 payments
All-time payments by company (2018-2024) ›
AbbVie, Inc.
$6,726
UCB, Inc.
$2,365
Janssen Biotech, Inc.
$1,807
AbbVie Inc.
$1,767
PFIZER INC.
$565
Amgen Inc.
$523
AstraZeneca Pharmaceuticals LP
$328
Novartis Pharmaceuticals Corporation
$317
Boehringer Ingelheim Pharmaceuticals, Inc.
$287
Abbott Laboratories
$205
GlaxoSmithKline, LLC.
$197
Aurinia Pharma U.S., Inc.
$171
Alexion Pharmaceuticals, Inc.
$161
Lilly USA, LLC
$140
Mallinckrodt Hospital Products Inc.
$134
Horizon Therapeutics plc
$124
GENZYME CORPORATION
$113
SOBI, INC
$91
Medtronic, Inc.
$66
Organon Llc
$66
Ardelyx, Inc.
$63
ABBVIE INC.
$61
Organon LLC
$52
ANI Pharmaceuticals, Inc.
$51
Fresenius Kabi USA, LLC
$49
Genentech USA, Inc.
$39
Actelion Pharmaceuticals US, Inc.
$38
Sandoz Inc.
$37
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$37
Celgene Corporation
$36
Boston Scientific Corporation
$34
E.R. Squibb & Sons, L.L.C.
$31
Clarius Mobile Health Corp.
$30
Sonex Health, Inc.
$22
Phathom Pharmaceuticals, Inc.
$19
Mylan Institutional Inc.
$18
Regeneron Healthcare Solutions, Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$17
Novo Nordisk Inc
$16
Fidia Pharma USA Inc.
$16
Nestle HealthCare Nutrition Inc.
$16
VIVUS LLC
$16
Radius Health, Inc.
$16
Merck Sharp & Dohme LLC
$14
INTERCEPT PHARMACEUTICALS, INC.
$14
QOL Medical, LLC
$13
Top 3 companies account for 64.4% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · BENLYSTA · COSENTYX · Cimzia · DIFICID · DUPIXENT · ENTYVIO · ETERNA · EVUSHELD · Enbrel · HADLIMA · HUMIRA · HYMOVIS · HYRIMOZ · Hulio · Humira · IBSRELA · IDACIO · INFLECTRA · INTELLIS ADAPTIVESTIM · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · OCALIVA · OCTRODE · OFEV · OMVOH · OPSUMIT · ORENCIA · Ozempic · PROCLAIM · PURIFIED CORTROPHIN GEL · QSYMIA · RENFLEXIS · RINVOQ · SAPHNELO · SKYRIZI · SOLIRIS · STELARA · STRENSIQ · SUCRAID · TALTZ · TAVNEOS · TREMFYA · Tymlos · UBRELVY · ULTOMIRIS · ULTRAGUIDECTR · VOQUEZNA · VYNDAQEL · XELJANZ · XIFAXAN · ZENPEP
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (49%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware.

Looking for a rheumatology specialist in Raleigh?
Compare rheumatologists in the Raleigh area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
42
Per 100K population
3.6
County median income
$101,763
Nearest hospital
TRIANGLE SPRINGS
8.9 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Chaudhary is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 17% of NC peers.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Chaudhary experienced with infliximab infusion (remicade)?
Based on Medicare claims data, Dr. Chaudhary performed 3,770 infliximab infusion (remicade) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chaudhary receive payments from pharmaceutical companies?
Yes. Dr. Chaudhary received a total of $16,921 from 46 companies across 251 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chaudhary's costs compare to other rheumatologists in Raleigh?
Dr. Chaudhary's average Medicare payment per service is $37. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chaudhary) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →